\
&
Contact us
\
&
Contact us
Published on | 4 years ago
Programmes MSCAMarie Skłodowska-Curie Actions (MSCA) Co-funding of regional, national and international programmes (Cofund) foresees co-funding for new or existing regional, national, and international doctoral and postdoctoral training programmes with an international, intersectoral and interdisciplinary research training, and transnational and cross-sectoral mobility of researchers.
For the MSCA Cofound 2020 call, with deadline 29 September 2020, 157 proposals were submitted, which is an increase of 18% compared to the 2019 call. Of these submitted proposals, 19 doctoral and 24 postdoctoral programmes have been approved to receive co-funding. Among these is one application with a Flemish coordinator:
Vrije Universiteit Brussel with fellowship programme “A dedicated postdoctoral research and training programme fostering impact development and entrepreneurship”
Press release MSCA website: Cofund 2020 call results
Press release European Commission website
Overview of submitted proposals and overview of percentage of proposals above the overall threshold and with a given score or higher per ranking list
Related news article
MSCA - Number of proposals submitted - 2020 COFUND call - deadline 29/9/2020
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
